These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 22751120)

  • 1. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
    Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
    Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth.
    Vellanki SH; Cruz RGB; Jahns H; Hudson L; Sette G; Eramo A; Hopkins AM
    Cancer Lett; 2019 Jan; 440-441():23-34. PubMed ID: 30312728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase.
    McSherry EA; Brennan K; Hudson L; Hill AD; Hopkins AM
    Breast Cancer Res; 2011 Mar; 13(2):R31. PubMed ID: 21429211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
    McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
    Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
    Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
    Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion.
    Wang Y; Lui WY
    Eur J Cancer; 2012 Dec; 48(18):3475-87. PubMed ID: 22647687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
    Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
    Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Junctional adhesion molecule-A, an epithelial-mesenchymal transition inducer, correlates with metastasis and poor prognosis in human nasopharyngeal cancer.
    Tian Y; Tian Y; Zhang W; Wei F; Yang J; Luo X; Zhou T; Hou B; Qian S; Deng X; Qiu Y; Yao K
    Carcinogenesis; 2015 Jan; 36(1):41-8. PubMed ID: 25416560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
    Pérez-Gómez E; Andradas C; Blasco-Benito S; Caffarel MM; García-Taboada E; Villa-Morales M; Moreno E; Hamann S; Martín-Villar E; Flores JM; Wenners A; Alkatout I; Klapper W; Röcken C; Bronsert P; Stickeler E; Staebler A; Bauer M; Arnold N; Soriano J; Pérez-Martínez M; Megías D; Moreno-Bueno G; Ortega-Gutiérrez S; Artola M; Vázquez-Villa H; Quintanilla M; Fernández-Piqueras J; Canela EI; McCormick PJ; Guzmán M; Sánchez C
    J Natl Cancer Inst; 2015 Jun; 107(6):djv077. PubMed ID: 25855725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer.
    Cruz RGB; Madden SF; Brennan K; Hopkins AM
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.